FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
Enhertu is projected to reach $13.9bn in sales by 2030, according to GlobalData’s Pharma Intelligence Center.
Cancer
Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
Vidac secures funding to advance skin cancer trials of novel ointment
AngioDynamics launches long-term study of NanoKnife for prostate cancer
Zymeworks doses first subject in Phase I trial of ZW171 for various forms of cancer
FDA gives Adcendo green light to trial ADC in Phase I/II sarcoma study
Ossium treats first leukaemia patient in cryopreserved bone marrow trial
